Alphatec secured exclusive U.S. rights to Theradaptive’s OsteoAdapt bone graft platform through a new partnership, according to a Jan. 12 news release.
Under the agreement Alphatec can market and distribute OsteoAdapt, a bone graft for spinal fusion, in the U.S. OsteoAdapt is an osteoinductive bone graft and is being evaluated in clinical trials for spine and dental use.
Theradaptive also launched a series B financing round to support clinical studies and scaling of OsteoAdapt.
